Pharmacologic Substance

Abivax aces pair of phase 3 ulcerative colitis trials as end of cash runway looms

10 hours ago talkbio0Tagged Abivax, ABTECT-1, ABTECT-2, cash runway, clinical remission, induction trials, maintenance trial, Obefazimod, Oral cavity, Ulcerative Colitis

Abivax; Obefazimod; ulcerative colitis; Phase 3 trial; clinical remission; ABTECT-1; ABTECT-2; cash runway; induction trials; oral miR-124 enhancer; maintenance trial

CorestemChemon Partners with ATG Lifetech to Expand Organoid and Transcriptomics Capabilities

10 hours ago talkbio0Tagged Blood - brain barrier anatomy, CorestemChemon, Drug Discovery, FDA/EMA regulatory pathways, Gene Expression Profiling, heart organoids, Lifetech, liver organoids, lymphocyte immune globulin, anti-thymocyte globulin, Organoids, preclinical CRO, Predictive analytics, Tumorigenicity

CorestemChemon; ATG Lifetech; organoids; transcriptomics; preclinical CRO; drug discovery; predictive analytics; tumorigenicity; FDA/EMA regulatory pathways; liver organoids; heart organoids; blood-brain barrier models

Scancell’s Cancer Vaccine Supercharges Melanoma Immunotherapy in Recent Trials

22 hours ago talkbio0Tagged Cancer Vaccines, checkpoint inhibitors, Clinical Trials, Immunotherapy, iSCIB1 +, melanoma, Melanoma TRP2 CTL Epitope Vaccine SCIB1, Scancell, SCOPE trial

Scancell; SCIB1; iSCIB1+; melanoma; cancer vaccine; immunotherapy; checkpoint inhibitors; clinical trial; SCOPE trial

GSK to Lay Off 150 Employees in Cambridge, Massachusetts Amid Vaccine Manufacturing Shift

1 day ago talkbio0Tagged biotech employment, Cambridge Massachusetts, Drug Industry, layoffs, Marietta Pennsylvania, site transfer, SmithKline Beecham, Vaccines

GSK; layoffs; Cambridge Massachusetts; vaccine manufacturing; site transfer; Marietta Pennsylvania; pharmaceutical industry; biotech employment

AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer

1 day ago talkbio0Tagged AstraZeneca, Benefit, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, life-extension, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Tagrisso

AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit

Avalyn Pharma Raises $100M to Advance Inhaled Lung Disease Drugs

1 day ago talkbio0Tagged AP01, AP02, aspects of adverse effects, Avalyn, Clinical Trials, drug safety, Holdings, inhaled lung disease, nintedanib, Pharma, pirfenidone, Pulmonary Fibrosis, Series D, SNCG gene, Suvretta Capital Management

Avalyn Pharma; $100 million Series D; inhaled lung disease medications; pulmonary fibrosis; AP01; AP02; pirfenidone; nintedanib; clinical trials; drug safety; side effects; Suvretta Capital Management; SR One; Novo Holdings

Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines

1 day ago talkbio0Tagged Acquisition, Homo sapiens, Metapneumovirus, Molecular Clamp Technology, non-mRNA vaccine, Respiratory syncytial virus, respiratory vaccines, RSV, sanofi, vaccine pipeline, Vaccines, Combined, Vicebio

Sanofi; Vicebio; acquisition; RSV; human metapneumovirus; combination vaccine; Molecular Clamp technology; non-mRNA vaccine; vaccine pipeline; respiratory vaccines

Replimune’s Shares Plunge After FDA Rejects Melanoma Drug Application

1 day ago talkbio0Tagged Antineoplastic Agents, Clinical Trial Design, Complete, Drops - Drug Form, Frequency of Responses, melanoma, Prices, Rejection, Replimune, Response Letter, RETINITIS PIGMENTOSA 1, United States Food and Drug Administration

Replimune; RP1; FDA rejection; melanoma; cancer drug; Complete Response Letter; clinical trial design; objective response rate; share price drop

AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia

1 day ago talkbio0Tagged AstraZeneca, Chronic disease, Investments, Manufacturing, R&D, Surgical construction, tariffs, United States, Virginia plant

AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals

Alkermes Advances Narcolepsy Therapy with Promising Phase 2 Trial Results for Alixorexton

2 days ago talkbio0Tagged alixorexton, Alkermes, Cataplexy, Daytime Somnolence, Excessive (qualifier value), late-stage testing, Narcolepsy, Narcolepsy type 1, normative wakefulness, Orexin Receptor Agonist, Vibrance-1 study

Alkermes; narcolepsy; alixorexton; Phase 2 trial; orexin 2 receptor agonist; narcolepsy type 1; normative wakefulness; late-stage testing; Vibrance-1 study; cataplexy; excessive daytime sleepiness